Men with metastatic castration-resistant prostate cancer (CRPC) lived significantly longer when treated with a bone-targeted, alpha-emitting agent, a randomized trial showed.
Men with metastatic castration-resistant prostate cancer (CRPC) lived significantly longer when treated with a bone-targeted, alpha-emitting agent, a randomized trial showed.